Summary of Study ST001902
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001197. The data can be accessed directly via it's Project DOI: 10.21228/M8041N This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001902 |
| Study Title | Metabolomics analysis of AsPC-1 PDAC cells treated with Porcupine inhibitor (LGK974) |
| Study Summary | WNT signaling promotes pancreatic ductal adenocarcinoma (PDAC) through diverse effects on proliferation, differentiation, survival, and stemness. A subset of PDAC with inactivating mutations in ring finger protein 43 (RNF43) have growth dependency on autocrine WNT ligand signaling, which renders them susceptible to porcupine inhibitors (PORCNi) that block WNT ligand acylation and secretion. For this study, non-targeted metabolomic analyses were performed to explore the therapeutic response of RNF43-mutant PDAC to the PORCNi LGK974. AsPC-1 (RNF43-mutant) PDAC cells were treated with 25 nM LGK974 to explore stable isotope-resolved metabolomics with uniform 1, D-glucose [U13-C6] labeling. |
| Institute | University of California, Los Angeles |
| Department | Pathology & Laboratory Medicine |
| Laboratory | Dawson Lab |
| Last Name | Dawson |
| First Name | David |
| Address | 10833 LeConte Avenue |
| ddawson@mednet.ucla.edu | |
| Phone | 310-825-0618 |
| Submit Date | 2021-07-19 |
| Num Groups | 2 |
| Total Subjects | 6 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | API-MS |
| Release Date | 2022-04-19 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR001992 |
| Treatment Summary: | AsPC-1 PDAC cells were plated at 500,000 cells per well in 6 well plates in ultra-low attachment conditions. Cells were pre-treated with 25 nM LGK974 or DMSO vehicle control for 12 hours, maintained in normal media conditions. Media was exchanged with [13C6] glucose labeling media and cells were re-treated with 25 nM LGK974 or DMSO vehicle control for 24 hours. |
